新光药业(300519) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥67,075,377.49, a decrease of 27.08% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2023 was ¥20,160,102.38, down 29.49% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥19,593,617.82, reflecting a 31.98% decline compared to the previous year[5] - Total operating revenue for the third quarter was CNY 216.11 million, a decrease of 17.7% compared to CNY 262.45 million in the same period last year[19] - Net profit for the third quarter was CNY 58.70 million, representing a decline of 34.3% from CNY 89.40 million in the previous year[20] - Earnings per share for the third quarter were CNY 0.37, down from CNY 0.56 in the same quarter last year[20] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥919,269,079.44, a decrease of 4.02% from the end of the previous year[5] - The company's total current assets as of September 30, 2023, amount to ¥777,543,459.59, a decrease from ¥812,262,950.53 at the beginning of the year[16] - The total assets of the company as of September 30, 2023, are ¥919,269,079.44, down from ¥957,759,191.66 at the start of the year[16] - The total liabilities of the company as of September 30, 2023, are ¥71,211,819.77, a decrease from ¥88,367,651.86 at the beginning of the year[16] - Total liabilities amounted to CNY 81.25 million, a decrease from CNY 98.86 million in the previous year[20] Cash Flow - Cash flow from operating activities for the year-to-date was ¥41,748,650.66, a significant decrease of 55.36% compared to the same period last year[5] - Cash flow from operating activities generated a net amount of CNY 41.75 million, significantly lower than CNY 93.52 million in the previous year[22] - The net cash flow from investing activities increased by 143.37% to ¥20,486,792.61, mainly due to increased redemption of financial products[9] - The company reported a net cash flow from investment activities of CNY 20.49 million, an increase from CNY 8.42 million year-over-year[22] - Cash flow from financing activities decreased to -80 million from -96 million year-over-year[23] - The net increase in cash and cash equivalents was -17.76 million compared to an increase of 5.94 million in the previous year[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,152[10] - The largest shareholder, Wang Yuejun, holds 38.25% of the shares, totaling 61,200,000 shares[10] - The number of restricted shares held by Wang Yuejun remains at 45,900,000, with no shares released during the period[13] - The company has no preferred shareholders as indicated in the report[12] Inventory and Receivables - Accounts receivable decreased by 30.82% to ¥16,467,773.43 due to reduced shipments compared to the previous year[8] - Inventory increased by 29.93% to ¥59,957,414.26, attributed to decreased shipments at the end of the reporting period[8] - The inventory level has increased to ¥59,957,414.26 from ¥46,146,719.95 at the beginning of the year[15] Financial Expenses and Equity - The company reported a 54.12% increase in financial expenses, totaling -¥13,066,151.75, primarily due to increased bank deposit interest[8] - The total equity attributable to shareholders was CNY 838.02 million, down from CNY 858.89 million year-over-year[20] - Deferred income tax liabilities increased to CNY 502.06 million from CNY 426.23 million in the previous year[20] Strategic Developments - The company has not reported any new strategies or significant market expansions in the current quarter[14]